Nécrolyse épidermique toxique due à l’ipilimumab et au nivolumab chez une patiente souffrant d’un mélanome métastatique
- 5 July 2021
- journal article
- editorial
- Published by Canadian Society of Healthcare-Systems Pharmacy in The Canadian Journal of Hospital Pharmacy
- Vol. 74 (3) , 294-297
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature ReviewJournal of Immunotherapy, 2019
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapiesCancer Management and Research, 2018
- Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphomaJAAD Case Reports, 2018
- Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsCancer Treatment Reviews, 2017
- Toxic Epidermal Necrolysis–like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic MelanomaJournal of Immunotherapy, 2016
- ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control AnalysisClinical Pharmacology & Therapeutics, 2010
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981